Santarelli Ignacio Martín, Manzella Pedro Oscar, Gasco González Francisco, Ingold Julián José, Olivieri Melissa Alejandra, Cloobs Venezia Maximiliano Ariel, Fernández Sofía Isabel, Melero Marcelo José
Hospital de Clínicas José de San Martín.
Hospital de Clinicas "José de San Martín", Universidad de Buenos Aires.
Rev Fac Cien Med Univ Nac Cordoba. 2022 Jun 6;79(2):201-204. doi: 10.31053/1853.0605.v79.n2.35138.
The hepatitis-associated aplastic anemia is one of the acquired bone marrow failure syndromes. It is a stereotyped form of presentation of aplastic anemia and accounts for 2 - 5 % of the cases in the West. Its treatment, which does not differ from that of aplastic anemia, consists of immunosuppression when bone marrow transplant is not possible. Nonetheless, during the SARS-CoV-2 pandemic, recommendations restricting the use of antithymocyte globulin to those cases with the highest risk of death have been issued, since the prognosis of CoViD-19 tends to be worse if administered. We present an otherwise-healthy 18-year-old male who was diagnosed with a hepatitis-associated aplastic anemia and received a personalized treatment following these recommendations.
肝炎相关性再生障碍性贫血是获得性骨髓衰竭综合征之一。它是再生障碍性贫血的一种典型表现形式，在西方占所有病例的2%至5%。其治疗方法与再生障碍性贫血的治疗方法并无不同，在无法进行骨髓移植时采用免疫抑制治疗。尽管如此，在2019冠状病毒病大流行期间，已发布建议，将抗胸腺细胞球蛋白的使用限制在死亡风险最高的病例中，因为如果使用该药物，新冠病毒疾病的预后往往会更差。我们报告一名18岁的健康男性，他被诊断为肝炎相关性再生障碍性贫血，并根据这些建议接受了个性化治疗。
